Drug Trial Radar · NCT00402077
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Last checked: Nov 20, 2026Latest source record: Mar 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Nov 2006
Primary completion
Aug 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
Conditions
- Overweight
- Obesity
Interventions
pramlintide acetateDrug
subcutaneous injection, three times a day, 120mcg
sibutramineDrug
oral tablet, once a day, 10mg
phentermineDrug
oral tablet, once a day, 37.5mg
placeboDrug
subcutaneous injection, three times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- All treatment-emergent adverse events occurring during the 24-week treatment periodTime frame: 24 weeks
- Absolute change in body weight from baseline to Week 12Time frame: 12 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Phoenix, Arizona
Research Site
Chula Vista, California
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Walnut Creek, California
Research Site
Miami, Florida
Research Site
Pembroke Pines, Florida
Research Site
Louisville, Kentucky
Research Site
New York, New York
Research Site
Raleigh, North Carolina
Research Site
Statesville, North Carolina
Research Site
Eugene, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Austin, Texas
Research Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.